Cargando…

Immunological Subsets Characterization in Newly Diagnosed Relapsing–Remitting Multiple Sclerosis

OBJECTIVES: Using flow cytometry, we characterized myeloid, B, and T cells in patients recently diagnosed with relapsing–remitting multiple sclerosis (RRMS) naive to disease-modifying therapies (DMTs). METHODS: This prospective case–control study was conducted in the tertiary MS center of Catania, I...

Descripción completa

Detalles Bibliográficos
Autores principales:	D’Amico, Emanuele, Zanghì, Aurora, Parrinello, Nunziatina Laura, Romano, Alessandra, Palumbo, Giuseppe Alberto, Chisari, Clara Grazia, Toscano, Simona, Raimondo, Francesco Di, Zappia, Mario, Patti, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902351/ https://www.ncbi.nlm.nih.gov/pubmed/35273601 http://dx.doi.org/10.3389/fimmu.2022.819136

Ejemplares similares

The Neutrophil-to-Lymphocyte Ratio is Related to Disease Activity in Relapsing Remitting Multiple Sclerosis
por: D’Amico, Emanuele, et al.
Publicado: (2019)

Exploring polypharmacy phenomenon in newly diagnosed relapsing–remitting multiple sclerosis: a cohort ambispective single-centre study
por: Zanghì, Aurora, et al.
Publicado: (2021)

Pregnancy and the Postpartum Period in Women With Relapsing-Remitting Multiple Sclerosis Treated With Old and New Disease-Modifying Treatments: A Real-World Multicenter Experience
por: Zanghì, Aurora, et al.
Publicado: (2020)

Gonadal Steroids and Sperm Quality in a Cohort of Relapsing Remitting Multiple Sclerosis: A Case-Control Study
por: D'Amico, Emanuele, et al.
Publicado: (2020)

Reliability of televisits for patients with mild relapsing–remitting multiple sclerosis in the COVID-19 era
por: Toscano, Simona, et al.
Publicado: (2022)

Correction to: Reliability of televisits for patients with mild relapsing–remitting multiple sclerosis in the COVID‑19 era
por: Toscano, Simona, et al.
Publicado: (2022)

Mental health status of relapsing-remitting multiple sclerosis Italian patients returning to work soon after the easing of lockdown during COVID-19 pandemic: A monocentric experience
por: Zanghì, Aurora, et al.
Publicado: (2020)

A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives
por: D’Amico, Emanuele, et al.
Publicado: (2016)

Ofatumumab and Early Immunological Cells Subset Characterization in Naïve Relapsing Multiple Sclerosis Patients: A Real-World Study
por: D’Amico, Emanuele, et al.
Publicado: (2023)

Negative prognostic impact of MRI spinal lesions in the early stages of relapsing–remitting multiple sclerosis
por: D’Amico, E, et al.
Publicado: (2016)

Monocytic Myeloid Derived Suppressor Cells in Hematological Malignancies
por: Palumbo, Giuseppe Alberto, et al.
Publicado: (2019)

Cancer Risk and Multiple Sclerosis: Evidence From a Large Italian Cohort
por: D'Amico, Emanuele, et al.
Publicado: (2019)

Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience
por: D’Amico, Emanuele, et al.
Publicado: (2018)

MiRNA 106a-5p in cerebrospinal fluid as signature of early relapsing remitting multiple sclerosis: a cross sectional study
por: Zanghì, Aurora, et al.
Publicado: (2023)

Early-Onset Alcohol Dependence and Multiple Sclerosis: Diagnostic Challenges
por: Luca, Maria, et al.
Publicado: (2021)

Immunological Deregulation in Classic Hodgkin Lymphoma
por: Romano, Alessandra, et al.
Publicado: (2014)

Immunological Dysregulation in Multiple Myeloma Microenvironment
por: Romano, Alessandra, et al.
Publicado: (2014)

Stopping Interferon Beta 1b Does Not Influence the Risk of Disability Accrual in Non-Active SPMS: Results from an Italian Real-World Study
por: Zanghì, Aurora, et al.
Publicado: (2022)

PB2093: OVERALL SURVIVAL IN RELAPSED-REFRACTORY MYELOMA PATIENTS DEPENDS ON CIRCULATING PLASMA CELLS QUANTITATION
por: Parrinello, Nunziatina Laura, et al.
Publicado: (2023)

Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic
por: Zanghì, Aurora, et al.
Publicado: (2022)

The NLR and LMR ratio in newly diagnosed MM patients treated upfront with novel agents
por: Romano, Alessandra, et al.
Publicado: (2017)

A dynamic interpretation of κFLC index for the diagnosis of multiple sclerosis: a change of perspective
por: Toscano, Simona, et al.
Publicado: (2023)

First‐line therapies in late‐onset multiple sclerosis: An Italian registry study
por: Zanghì, Aurora, et al.
Publicado: (2021)

PB1993: EXPRESSION OF NEO-201 MAY HELP IN THE DIFFERENTIAL DIAGNOSIS BETWEEN MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA
por: Duminuco, Andrea, et al.
Publicado: (2023)

Multiple Sclerosis, COVID-19 and Vaccines: Making the Point
por: Toscano, Simona, et al.
Publicado: (2021)

Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets
por: Lundy, Steven K., et al.
Publicado: (2016)

Retinal Nerve Fiber Layer Thickness and Higher Relapse Frequency May Predict Poor Recovery after Optic Neuritis in MS Patients
por: Chisari, Clara Grazia, et al.
Publicado: (2019)

Bone turnover markers in patients with type 1 Gaucher disease
por: Giuffrida, Gaetano, et al.
Publicado: (2012)

Rituximab for the treatment of multiple sclerosis: a review
por: Chisari, Clara Grazia, et al.
Publicado: (2021)

Injectable versus oral first-line multiple sclerosis therapies: knows and unknowns from observational studies
por: D'Amico, Emanuele, et al.
Publicado: (2021)

Myeloid Derived Suppressor Cells (MDSCs) Are Increased and Exert Immunosuppressive Activity Together with Polymorphonuclear Leukocytes (PMNs) in Chronic Myeloid Leukemia Patients
por: Giallongo, Cesarina, et al.
Publicado: (2014)

Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis Patients: Monocentric Case Series and Systematic Review of the Literature
por: Patti, Francesco, et al.
Publicado: (2022)

Immunologic and MRI markers of the therapeutic effect of IFN-β-1a in relapsing-remitting MS
por: Tao, Yazhong, et al.
Publicado: (2015)

Lenalidomide and Pomalidomide Improve Function and Induce FcγRI/CD64 in Multiple Myeloma Neutrophils
por: Romano, Alessandra, et al.
Publicado: (2021)

PB2072: CIRCULATING CD71+ MYELOID PRECURSORS IN MGUS AND MULTIPLE MYELOMA: A PROSPECTIVE SURVEY
por: Parrinello, Nunziatina Laura, et al.
Publicado: (2023)

Proteomic Analysis Reveals Autophagy as Pro-Survival Pathway Elicited by Long-Term Exposure with 5-Azacitidine in High-Risk Myelodysplasia
por: Romano, Alessandra, et al.
Publicado: (2017)

Changes in John Cunningham Virus Index in Multiple Sclerosis Patients Treated with Different Disease-Modifying Therapies
por: Sgarlata, Eleonora, et al.
Publicado: (2022)

Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC)
por: Giallongo, Cesarina, et al.
Publicado: (2016)

The first description of a singular case of synchronous chronic myelomonocytic leukemia and diffuse large b‐cell lymphoma
por: Romano, Alessandra, et al.
Publicado: (2021)

A real‐world evidence study of nabiximols in multiple sclerosis patients with resistant spasticity: Analysis in relation to the newly described ‘spasticity‐plus syndrome’
por: Patti, Francesco, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_m84koqpbqs3v9mc4kp8r4j39gn